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c on c i s e c ommun i c a t i o n
Variability in Antifungal and Antiviral Use
in Hospitalized Children
Jennifer L. Goldman, MD, MS;1 Rachael K. Ross, MPH;2
Brian R. Lee, MPH, PhD;1 Jason G. Newland, MD, Med;3
Adam L. Hersh, MD, PhD;4 Matthew P. Kronman, MD,
MSCE;5 Jeffrey S. Gerber, MD, PhD2
We analyzed antifungal and antiviral prescribing among high-risk
children across freestanding children’s hospitals. Antifungal and anti-
viral days of therapy varied across hospitals. Benchmarking antifungal
and antiviral use and developing antimicrobial stewardship strategies to
optimize use of these high cost agents is needed.
Infect Control Hosp Epidemiol 2017;38:743–746
Antimicrobial stewardship programs (ASPs) have primarily
focused on the optimization of antibiotic therapy, whereas the
use of antifungal therapy and antiviral therapy has been
relatively ignored.1 Antifungal and antiviral medications are
often used for both treatment and prophylaxis for high-risk
conditions like those in oncology and transplant patients.
Furthermore, these agents are frequently associated with
adverse drug effects, and they are costly. Hospitalized patients
receiving these agents demand closer scrutiny to improve
patient outcomes and potentially reduce hospital expendi-
tures.2 The 2016 Infectious Diseases Society of America and
the Society for Healthcare Epidemiology of America ASP
guidelines recommend that stewardship should expand to
include antifungal therapy.3 Although prescribing trends of
antifungal and antiviral drugs among children are relatively
unknown, data suggest that their use is increasing.4 The
objectives of this study were (1) to characterize antifungal and
antiviral prescribing for hospitalized children including
comparison between high-risk and non–high-risk groups
and (2) to describe variability of antifungal and antiviral
prescribing among high-risk children to determine whether
there are potentially important pediatric stewardship targets.
methods
We performed a retrospective cohort study of antifungal and
antiviral prescribing in high risk hospitalized patients <18
years of age discharged between January 1 and December 31,
2015. Data were obtained from the Pediatric Health
Information System database, a clinical and administrative
database that contains inpatient demographic, diagnosis, and
prescribing charge data from 47 freestanding children’s
hospitals across the United States. We a priori identiﬁed
children considered to be at the highest risk for fungal or
viral infections, including those coded with an All Patient
Reﬁned Diagnosis Related Group (APR-DRG; version 32) for
oncology, bone marrow transplant, or solid organ transplant
(Table 1).
Antifungal therapy included ﬂuconazole, voriconazole,
posaconazole, itraconazole, amphotericin, caspofungin,
micafungin, anidulafungin, ﬂucytosine, or terbinaﬁne; anti-
viral therapy included charges for acyclovir, cidofovir, famci-
clovir, foscarnet, ganciclovir, oseltamivir, peramivir, ribavirin,
rimantadine, valacyclovir, valganciclovir, or zanamivir.
Data regarding age, race, gender, and receipt of any systemic
antifungal or antiviral therapy were collected. Total days of
antifungal or antiviral therapy (DOT) were standardized per
1,000 patient days. Summary statistics were constructed using
frequencies and proportions for categorical data and medians
and interquartile ranges (IQR) for continuous variables.
Analyses were performed with SAS version 9.4 software
(SAS Institute, Cary, NC) and Stata version 14.2 software
(StataCorp, College Station, TX). This study was not
considered human subject research by the Children’s Hospital
of Philadelphia Institutional Review Board.
results
In 2015, there were 784,240 inpatient discharges from the
47 hospitals included in our analysis; 35,211 (4.5%) of these
patients were classiﬁed as oncology, bone marrow transplant,
or solid organ transplant by APR-DRG. These high-risk
patients were predominately male (56%) and Caucasian
(63%), with a median age of 7.9 years (interquartile range
[IQR], 3.6–13.6). Among this high-risk cohort, chemotherapy
was the most common APR-DRG (54%), followed by major
hematologic/immunologic diagnosis (21%), acute leukemia
(7%), and bone marrow transplant (4%). Solid organ trans-
plants including heart, lung, liver, and kidney accounted for
approximately 3% of the total high-risk population.
Across all hospitalized patients, only 3% received antifungal
or antiviral therapy. In comparison, among the high-risk
patients, 19% received antifungal therapy and 12% received
antiviral therapy. These high-risk patients received 50% of all
antifungal DOT and 46% of all antiviral DOT despite
comprising <5% of all hospital discharges. Overall, high-risk
patients received 10 times more DOT than non–high-risk
patients: 389 antifungal DOT per 1,000 patient days versus
30 DOT, and 244 antiviral DOT per 1,000 patient days versus
22 DOT, respectively.
The highest percentage of prescribed antifungals (% total
DOT) occurred in patients hospitalized for bone marrow trans-
plant (20%), chemotherapy (10.5%), and acute leukemia (6.5%).
The highest percentage of prescribed antiviral (% total DOT)
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was used for children hospitalized for bone marrow transplant
(24.1%), heart and/or lung transplant (4.8%), and liver and/or
intestinal transplant (4.2%). Children hospitalized with a bone
marrow transplant were prescribed 845 DOT per 1,000 patient
days of antifungal therapy (range, 664–1194) and 685 DOT per
1,000 patient days of antiviral therapy (range, 358–1,048)
(Table 1).
Examination by drug class revealed total DOT rates
among high-risk patients as follows: ﬂuconazole, 135 DOT per
1,000 patient days; echinocandins, 127 DOT per 1,000 patient
days; voriconazole, 84 DOT per 1,000 patient days; and
amphotericin, 24 DOT per 1,000 patient days. Antiviral drugs
targeting herpes viruses (ie, acyclovir, cidofovir, famciclovir,
foscarnet, ganciclovir, ribavirin, valacyclovir, or valganciclovir)
were prescribed 241 DOT per 1,000 patient days. The prevalence
and total use of antifungal and antiviral therapy among high-risk
patients varied widely across hospitals (Figure 1): antifungal use
ranged from 75 to 608 DOT per 1,000 patient days and antiviral
use ranged from 18 to 451 DOT per 1,000 patient days across
centers. The correlation between AFT and AVT DOT rates
across hospitals was 0.58 (P< .001).
discussion
We examined antifungal and antiviral use among a high-risk
pediatric population admitted to 47 children’s hospitals. Our
results revealed (1) that this immune-compromised popula-
tion accounts for most antifungal and antiviral prescribing in
hospitals and (2) that variability in the use of these agents
exists, even when examining this relatively homogenous
cohort.
Variability in antimicrobial exposure has been observed in
high-risk pediatric patients, though previous work has focused
on antibacterial therapy.5 Antifungal and antiviral agents
table 1. Antifungal and Antiviral Therapy Prescribing Among High-Risk Children in 47 Freestanding Children’s Hospitals
Antifungal Therapy Antiviral Therapy











Chemotherapy 18,884 12 257 5 70
Major hematologic/immunologic diagnosis except
sickle cell crisis & coagulopathy
7,474 20 306 11 148
Acute leukemia 2,431 34 460 11 100
Bone marrow transplant 1,323 93 845 80 685
Nervous system malignancy 772 6 66 3 25
Other or prophylaxis for lymphatic/hematopoietic/
other neoplasms
500 19 434 7 92
Musculoskeletal malignancy & related pathological
fractures
488 4 36 4 45
Lymphoma, myeloma & nonacute leukemia 459 19 279 10 80
Major or prophylaxis for lymphatic/hematopoietic/
other neoplasms
434 26 443 6 94
Kidney transplant 363 21 116 88 656
Heart &/or lung transplant 362 41 125 83 308
Kidney & urinary tract procedures for malignancy 336 4 41 0 0
Liver transplant &/or intestinal transplant 332 71 459 94 626
Radiotherapy 274 2 101 1 31
Lymphatic & other malignancies & neoplasms of
uncertain behavior
264 10 131 5 62
Malignancy of hepatobiliary system & pancreas 115 9 151 3 11
Kidney & urinary tract malignancy 100 4 30 1 5
Ear, nose, mouth, throat, cranial/facial malignancies 93 9 110 2 23
Respiratory malignancy 78 6 55 8 36
Digestive malignancy 44 16 233 9 141
Uterine & adnexa procedures for ovarian & adnexal
malignancy
39 0 0 0 0
Female reproductive system malignancy 26 15 250 4 73
Malignancy, male reproductive system 15 0 0 7 34
Uterine & adnexa prophylaxis for nonovarian &
nonadnexal malignancy
5 40 159 0 0
NOTE. DOT, days of therapy.
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represent important stewardship targets because they (1) are
often used for the treatment or prevention of relatively
high-risk infections, (2) can be associated with a relatively high
rate of adverse drug effects, (3) often require challenging
therapeutic drug monitoring, and (4) are disproportionately
costly relative to utilization.2,6,7 Although guidelines have been
developed to address antifungal and antiviral therapy in
oncology and transplant patients,8,9 our data demonstrate
that prescribing variability exists and more can be done to
standardize practice and minimize unnecessary use.
Antimicrobial stewardship programs have been shown to
enhance judicious antibacterial prescribing practices, improve
clinical outcomes, and reduce healthcare costs.3 Antifungal
stewardship can be effective by optimizing therapy and
decreasing unnecessary use resulting in cost savings.10
Currently, the available antifungal and antiviral therapies are
limited, making stewardship critically important, as efforts to
avoid the development of drug resistance and unnecessary
adverse drug effects are needed. Invasive fungal and viral
infections in the immunocompromised host can be devastating,
resulting in high rates of morbidity and mortality. Selecting the
most effective therapeutic agent, optimizing therapeutic dosing,
and using therapeutic drug monitoring when available are all
potentially effective points for stewardship interventions in this
vulnerable population.
Our study has limitations. This study was limited to free-
standing children’s hospitals and may not be generalizable to
other clinical settings. We were unable to discriminate between
treatment and prophylaxis, and we did not assess appro-
priateness of use. Antifungals and antivirals were determined
using charge data, not medication administration information.
Nonetheless, antifungal and antiviral use varied broadly across
hospitals, even when comparing use in similar, high-risk
patients. Benchmarking antifungal and antiviral is an important
step in identifying targeted stewardship strategies to enhance
judicious antimicrobial prescribing.
ﬁgure 1. Variability in antifungal and antiviral therapy prescribing among high-risk children in 47 freestanding children’s hospitals.
Panel A: antifungal therapy. Panel B: antiviral therapy. Gray bars: left y-axis depicts DOT per 1,000 patient days. Black dots: right y-axis
depicts percentage of patients who were prescribed therapy. DOT, days of therapy.
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